| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 44 | 2024 | 184 | 7.070 |
Why?
|
| Ischemic Preconditioning | 21 | 2016 | 48 | 3.340 |
Why?
|
| Nerve Tissue Proteins | 17 | 2013 | 360 | 2.730 |
Why?
|
| Neurons | 44 | 2024 | 1175 | 2.350 |
Why?
|
| Stroke | 16 | 2020 | 286 | 2.320 |
Why?
|
| Brain | 27 | 2020 | 1346 | 2.130 |
Why?
|
| Sodium Channels | 14 | 2011 | 67 | 2.020 |
Why?
|
| Membrane Proteins | 14 | 2011 | 517 | 1.670 |
Why?
|
| Hippocampus | 25 | 2020 | 561 | 1.450 |
Why?
|
| Animals | 92 | 2024 | 15081 | 1.220 |
Why?
|
| Seizures | 11 | 2012 | 68 | 1.150 |
Why?
|
| Acidosis | 11 | 2024 | 51 | 1.090 |
Why?
|
| Neuroprotective Agents | 16 | 2024 | 245 | 1.040 |
Why?
|
| Nerve Degeneration | 7 | 2011 | 107 | 0.990 |
Why?
|
| Mice | 55 | 2024 | 5913 | 0.980 |
Why?
|
| Epilepsy | 9 | 2012 | 43 | 0.960 |
Why?
|
| Reperfusion Injury | 3 | 2018 | 57 | 0.890 |
Why?
|
| Rats | 36 | 2022 | 3483 | 0.860 |
Why?
|
| DNA Repair | 3 | 2018 | 188 | 0.840 |
Why?
|
| Protons | 3 | 2022 | 84 | 0.820 |
Why?
|
| Infarction, Middle Cerebral Artery | 15 | 2020 | 77 | 0.820 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 175 | 0.800 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2018 | 22 | 0.780 |
Why?
|
| Calcium | 14 | 2020 | 480 | 0.760 |
Why?
|
| Gene Expression Regulation | 9 | 2011 | 1015 | 0.730 |
Why?
|
| Ischemia | 4 | 2022 | 46 | 0.730 |
Why?
|
| Cells, Cultured | 25 | 2024 | 1518 | 0.700 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2011 | 239 | 0.640 |
Why?
|
| Gene Expression | 3 | 2015 | 674 | 0.630 |
Why?
|
| Cerebral Cortex | 13 | 2016 | 290 | 0.590 |
Why?
|
| Disease Models, Animal | 22 | 2018 | 1371 | 0.590 |
Why?
|
| Brain Injuries | 4 | 2017 | 121 | 0.580 |
Why?
|
| Ubiquitin | 3 | 2008 | 78 | 0.570 |
Why?
|
| Cricetulus | 8 | 2024 | 80 | 0.550 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2008 | 114 | 0.550 |
Why?
|
| Mice, Knockout | 13 | 2024 | 933 | 0.530 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 2004 | 40 | 0.530 |
Why?
|
| Rats, Sprague-Dawley | 18 | 2016 | 1618 | 0.510 |
Why?
|
| Male | 54 | 2024 | 20025 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 22 | 2024 | 1609 | 0.510 |
Why?
|
| Cell Death | 14 | 2012 | 267 | 0.510 |
Why?
|
| Genomics | 3 | 2017 | 223 | 0.510 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2011 | 147 | 0.490 |
Why?
|
| Carrier Proteins | 8 | 2008 | 305 | 0.470 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 219 | 0.470 |
Why?
|
| Hydrogen-Ion Concentration | 11 | 2022 | 364 | 0.470 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2007 | 190 | 0.470 |
Why?
|
| Caspases | 7 | 2006 | 147 | 0.460 |
Why?
|
| Globins | 1 | 2013 | 9 | 0.450 |
Why?
|
| Epilepsy, Temporal Lobe | 4 | 2012 | 17 | 0.430 |
Why?
|
| Neurogenesis | 1 | 2013 | 58 | 0.430 |
Why?
|
| Apoptosis | 11 | 2008 | 1398 | 0.420 |
Why?
|
| DNA Glycosylases | 3 | 2018 | 16 | 0.400 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2022 | 86 | 0.370 |
Why?
|
| CHO Cells | 8 | 2024 | 124 | 0.370 |
Why?
|
| Membrane Potentials | 8 | 2016 | 223 | 0.370 |
Why?
|
| Phenotype | 3 | 2009 | 689 | 0.370 |
Why?
|
| Signal Transduction | 11 | 2022 | 1908 | 0.370 |
Why?
|
| Electroencephalography | 8 | 2016 | 116 | 0.370 |
Why?
|
| Cricetinae | 8 | 2024 | 238 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2005 | 152 | 0.350 |
Why?
|
| Kainic Acid | 13 | 2012 | 48 | 0.350 |
Why?
|
| Cytoprotection | 2 | 2008 | 36 | 0.350 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 105 | 0.340 |
Why?
|
| Adenosine Kinase | 6 | 2008 | 9 | 0.340 |
Why?
|
| Status Epilepticus | 4 | 2011 | 12 | 0.330 |
Why?
|
| Humans | 34 | 2020 | 37093 | 0.330 |
Why?
|
| Cerebrovascular Circulation | 3 | 2007 | 70 | 0.320 |
Why?
|
| Glutamic Acid | 2 | 2011 | 128 | 0.320 |
Why?
|
| Vitamin A | 1 | 2008 | 87 | 0.310 |
Why?
|
| Lipopolysaccharides | 5 | 2011 | 220 | 0.310 |
Why?
|
| Brain Infarction | 2 | 2012 | 20 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2012 | 356 | 0.310 |
Why?
|
| Cell Membrane | 1 | 2010 | 381 | 0.300 |
Why?
|
| Membrane Glycoproteins | 3 | 2012 | 211 | 0.300 |
Why?
|
| Calcineurin | 1 | 2007 | 22 | 0.300 |
Why?
|
| Stem Cells | 1 | 2008 | 141 | 0.290 |
Why?
|
| In Situ Nick-End Labeling | 7 | 2006 | 133 | 0.280 |
Why?
|
| Reperfusion | 4 | 2018 | 16 | 0.280 |
Why?
|
| Synapses | 1 | 2008 | 180 | 0.280 |
Why?
|
| Neurodegenerative Diseases | 1 | 2007 | 131 | 0.270 |
Why?
|
| MicroRNAs | 4 | 2012 | 426 | 0.270 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 137 | 0.270 |
Why?
|
| Proprotein Convertase 2 | 2 | 2020 | 21 | 0.260 |
Why?
|
| Neuropeptides | 2 | 2009 | 59 | 0.250 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 54 | 0.250 |
Why?
|
| Carboxypeptidase H | 1 | 2004 | 5 | 0.250 |
Why?
|
| Amiloride | 4 | 2016 | 18 | 0.240 |
Why?
|
| Tyrosine 3-Monooxygenase | 5 | 2004 | 78 | 0.240 |
Why?
|
| Hibernation | 1 | 2003 | 7 | 0.230 |
Why?
|
| N-Methylaspartate | 2 | 2022 | 57 | 0.230 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2003 | 2 | 0.230 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2023 | 3 | 0.230 |
Why?
|
| Immunohistochemistry | 7 | 2008 | 893 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 20 | 0.220 |
Why?
|
| Proteins | 5 | 2011 | 369 | 0.210 |
Why?
|
| Blotting, Western | 9 | 2012 | 859 | 0.210 |
Why?
|
| Time Factors | 9 | 2011 | 1742 | 0.200 |
Why?
|
| Proteomics | 3 | 2014 | 325 | 0.200 |
Why?
|
| Mammals | 1 | 2022 | 105 | 0.200 |
Why?
|
| Mitochondria | 6 | 2020 | 487 | 0.200 |
Why?
|
| Thrombolytic Therapy | 2 | 2018 | 17 | 0.190 |
Why?
|
| Proteome | 2 | 2014 | 144 | 0.190 |
Why?
|
| Enzyme Inhibitors | 6 | 2008 | 433 | 0.190 |
Why?
|
| Excitatory Postsynaptic Potentials | 2 | 2020 | 79 | 0.190 |
Why?
|
| Amygdala | 5 | 2011 | 114 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2007 | 168 | 0.190 |
Why?
|
| Dynamins | 1 | 2020 | 16 | 0.180 |
Why?
|
| Maze Learning | 1 | 2020 | 105 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2020 | 928 | 0.170 |
Why?
|
| Extracellular Fluid | 2 | 2011 | 13 | 0.170 |
Why?
|
| In Situ Hybridization | 4 | 2012 | 129 | 0.160 |
Why?
|
| Analysis of Variance | 6 | 2012 | 550 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 1039 | 0.160 |
Why?
|
| Patch-Clamp Techniques | 5 | 2016 | 223 | 0.160 |
Why?
|
| 14-3-3 Proteins | 5 | 2004 | 22 | 0.150 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 4 | 0.150 |
Why?
|
| Nuclear Proteins | 6 | 2010 | 307 | 0.150 |
Why?
|
| Embryo, Mammalian | 3 | 2016 | 153 | 0.150 |
Why?
|
| Protein Kinases | 3 | 2007 | 100 | 0.150 |
Why?
|
| Down-Regulation | 5 | 2011 | 435 | 0.150 |
Why?
|
| Female | 14 | 2020 | 20969 | 0.150 |
Why?
|
| Adenosine | 5 | 2007 | 59 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2006 | 21 | 0.140 |
Why?
|
| RNA, Messenger | 7 | 2009 | 1207 | 0.140 |
Why?
|
| Up-Regulation | 9 | 2012 | 513 | 0.140 |
Why?
|
| Histone Code | 1 | 2015 | 13 | 0.130 |
Why?
|
| RNA | 1 | 2017 | 241 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 187 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 306 | 0.130 |
Why?
|
| Sleep | 1 | 2016 | 152 | 0.130 |
Why?
|
| Pyramidal Cells | 3 | 2006 | 63 | 0.120 |
Why?
|
| Zinc | 2 | 2007 | 128 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2020 | 623 | 0.120 |
Why?
|
| Ion Channel Gating | 1 | 2014 | 83 | 0.120 |
Why?
|
| Sensory Receptor Cells | 1 | 2014 | 32 | 0.120 |
Why?
|
| Olfactory Bulb | 1 | 2014 | 48 | 0.120 |
Why?
|
| Microarray Analysis | 3 | 2009 | 61 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2003 | 34 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 25 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 105 | 0.110 |
Why?
|
| Adaptation, Physiological | 2 | 2012 | 109 | 0.110 |
Why?
|
| Sex Factors | 2 | 2013 | 898 | 0.110 |
Why?
|
| Calcium Channels | 2 | 2011 | 76 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2003 | 121 | 0.110 |
Why?
|
| Glucose | 3 | 2011 | 230 | 0.110 |
Why?
|
| Animals, Newborn | 3 | 2009 | 343 | 0.110 |
Why?
|
| Sclerosis | 1 | 2012 | 6 | 0.110 |
Why?
|
| Killifishes | 1 | 2012 | 2 | 0.110 |
Why?
|
| Microinjections | 2 | 2002 | 57 | 0.110 |
Why?
|
| Tetrazolium Salts | 2 | 2011 | 36 | 0.110 |
Why?
|
| Ribonuclease III | 1 | 2012 | 10 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 13 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2015 | 325 | 0.110 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2012 | 1 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 234 | 0.110 |
Why?
|
| Aminoquinolines | 1 | 2012 | 14 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 103 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 99 | 0.100 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 59 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2003 | 444 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2013 | 233 | 0.100 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 626 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2011 | 17 | 0.100 |
Why?
|
| Imidazoles | 1 | 2012 | 126 | 0.100 |
Why?
|
| Lidocaine | 1 | 2011 | 17 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 51 | 0.100 |
Why?
|
| Protein Transport | 2 | 2010 | 302 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2011 | 61 | 0.100 |
Why?
|
| Bromodeoxyuridine | 2 | 2008 | 24 | 0.100 |
Why?
|
| TRPM Cation Channels | 1 | 2011 | 35 | 0.090 |
Why?
|
| Osteopontin | 2 | 2008 | 36 | 0.090 |
Why?
|
| Spermine | 1 | 2011 | 64 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 75 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2009 | 3 | 0.090 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2009 | 7 | 0.090 |
Why?
|
| Medication Errors | 1 | 2009 | 6 | 0.090 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 3 | 0.090 |
Why?
|
| Genes, Regulator | 1 | 2009 | 25 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 190 | 0.090 |
Why?
|
| Documentation | 1 | 2009 | 17 | 0.090 |
Why?
|
| Electric Conductivity | 2 | 2007 | 51 | 0.090 |
Why?
|
| Propidium | 2 | 2007 | 19 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 41 | 0.090 |
Why?
|
| Patient Admission | 1 | 2009 | 41 | 0.090 |
Why?
|
| Caspase 7 | 3 | 2007 | 16 | 0.090 |
Why?
|
| Receptors, Glutamate | 2 | 2011 | 27 | 0.090 |
Why?
|
| Calcium Signaling | 2 | 2014 | 101 | 0.090 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 12 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2011 | 272 | 0.080 |
Why?
|
| Molecular Sequence Data | 4 | 2008 | 1568 | 0.080 |
Why?
|
| Cell Nucleus | 3 | 2006 | 366 | 0.080 |
Why?
|
| Dynorphins | 1 | 2009 | 14 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 146 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2011 | 99 | 0.080 |
Why?
|
| Models, Neurological | 2 | 2007 | 128 | 0.080 |
Why?
|
| Diazepam | 3 | 2004 | 12 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 58 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2013 | 1369 | 0.080 |
Why?
|
| Convulsants | 2 | 2012 | 5 | 0.080 |
Why?
|
| Memory | 1 | 2010 | 170 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 123 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2008 | 10 | 0.080 |
Why?
|
| Epilepsies, Partial | 1 | 2008 | 3 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2008 | 167 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 33 | 0.080 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Carbocyanines | 1 | 2008 | 14 | 0.080 |
Why?
|
| Biomimetic Materials | 1 | 2008 | 23 | 0.080 |
Why?
|
| Insulin | 1 | 2010 | 236 | 0.080 |
Why?
|
| Vitamins | 1 | 2008 | 94 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2007 | 9 | 0.080 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 16 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 69 | 0.080 |
Why?
|
| Lentivirus | 1 | 2007 | 21 | 0.080 |
Why?
|
| Sodium Channel Blockers | 2 | 2004 | 17 | 0.080 |
Why?
|
| Kindling, Neurologic | 1 | 2007 | 3 | 0.080 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2007 | 8 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2010 | 249 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 1180 | 0.070 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2007 | 33 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2005 | 269 | 0.070 |
Why?
|
| Electrophysiology | 4 | 2010 | 136 | 0.070 |
Why?
|
| Dizocilpine Maleate | 1 | 2007 | 48 | 0.070 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2007 | 62 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 213 | 0.070 |
Why?
|
| Middle Aged | 6 | 2017 | 10129 | 0.070 |
Why?
|
| Endodeoxyribonucleases | 2 | 2006 | 29 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 122 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 59 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 52 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 308 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 31 | 0.070 |
Why?
|
| Electric Stimulation | 3 | 2016 | 184 | 0.070 |
Why?
|
| bcl-Associated Death Protein | 2 | 2004 | 9 | 0.070 |
Why?
|
| Ions | 1 | 2006 | 61 | 0.070 |
Why?
|
| RNA Interference | 1 | 2007 | 243 | 0.070 |
Why?
|
| Leupeptins | 1 | 2006 | 11 | 0.070 |
Why?
|
| Deoxyribonucleases | 1 | 2006 | 25 | 0.070 |
Why?
|
| Butadienes | 1 | 2006 | 29 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 39 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2004 | 77 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 55 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 103 | 0.070 |
Why?
|
| Lamins | 2 | 2002 | 5 | 0.070 |
Why?
|
| Caspase 6 | 2 | 2002 | 5 | 0.070 |
Why?
|
| Base Sequence | 2 | 2010 | 997 | 0.070 |
Why?
|
| Lamin Type A | 2 | 2002 | 13 | 0.070 |
Why?
|
| Staurosporine | 2 | 2002 | 38 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 176 | 0.070 |
Why?
|
| Nitriles | 1 | 2006 | 69 | 0.070 |
Why?
|
| Astrocytes | 2 | 2008 | 255 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 11 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 53 | 0.060 |
Why?
|
| Organ Culture Techniques | 2 | 2020 | 103 | 0.060 |
Why?
|
| Glioma | 2 | 2002 | 79 | 0.060 |
Why?
|
| Adult | 6 | 2017 | 11712 | 0.060 |
Why?
|
| Endotoxins | 1 | 2004 | 18 | 0.060 |
Why?
|
| COS Cells | 1 | 2004 | 69 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 56 | 0.060 |
Why?
|
| Cholestanols | 1 | 2024 | 5 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2004 | 21 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 502 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2004 | 75 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2004 | 61 | 0.060 |
Why?
|
| Bleeding Time | 1 | 2003 | 5 | 0.060 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2003 | 3 | 0.060 |
Why?
|
| Biophysics | 2 | 2016 | 37 | 0.060 |
Why?
|
| Protein Binding | 4 | 2011 | 972 | 0.060 |
Why?
|
| Cycloheximide | 3 | 2009 | 30 | 0.060 |
Why?
|
| Cell Survival | 2 | 2004 | 864 | 0.060 |
Why?
|
| Sequence Homology | 1 | 2003 | 34 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2003 | 19 | 0.060 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2003 | 14 | 0.060 |
Why?
|
| DNA Damage | 1 | 2006 | 352 | 0.060 |
Why?
|
| Cell Count | 1 | 2003 | 135 | 0.060 |
Why?
|
| Dendrites | 1 | 2003 | 55 | 0.060 |
Why?
|
| Drug Design | 1 | 2004 | 162 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 661 | 0.060 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2003 | 7 | 0.060 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2003 | 4 | 0.060 |
Why?
|
| DNA Ligases | 1 | 2003 | 13 | 0.060 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2003 | 23 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2003 | 40 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 77 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2002 | 27 | 0.050 |
Why?
|
| DNA | 1 | 2006 | 574 | 0.050 |
Why?
|
| Alanine | 2 | 2014 | 30 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 59 | 0.050 |
Why?
|
| GABA Agonists | 1 | 2002 | 21 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 53 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2002 | 79 | 0.050 |
Why?
|
| Glycine | 1 | 2022 | 47 | 0.050 |
Why?
|
| Transfection | 2 | 2016 | 523 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 218 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1198 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 40 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2002 | 32 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 252 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 448 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 2017 | 191 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 148 | 0.050 |
Why?
|
| Neuroglia | 1 | 2002 | 124 | 0.050 |
Why?
|
| Oligonucleotides | 2 | 2011 | 49 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 474 | 0.050 |
Why?
|
| Hela Cells | 1 | 2002 | 366 | 0.050 |
Why?
|
| Caspase 8 | 3 | 2006 | 32 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2008 | 617 | 0.050 |
Why?
|
| Functional Laterality | 3 | 2006 | 80 | 0.050 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Mutation | 3 | 2011 | 1095 | 0.040 |
Why?
|
| Superoxides | 1 | 2020 | 53 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2011 | 62 | 0.040 |
Why?
|
| Aged | 4 | 2013 | 6741 | 0.040 |
Why?
|
| Aging | 1 | 2004 | 664 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2020 | 120 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 2 | 2011 | 48 | 0.040 |
Why?
|
| Models, Animal | 2 | 2012 | 134 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 681 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 188 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 409 | 0.040 |
Why?
|
| Military Medicine | 1 | 2017 | 10 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 1378 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2009 | 21 | 0.040 |
Why?
|
| Propionates | 1 | 2016 | 26 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 61 | 0.030 |
Why?
|
| Military Personnel | 1 | 2017 | 90 | 0.030 |
Why?
|
| Caspase 9 | 2 | 2007 | 30 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 83 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 562 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 166 | 0.030 |
Why?
|
| DNA Fragmentation | 2 | 2007 | 92 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2379 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 515 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2007 | 158 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2006 | 13 | 0.030 |
Why?
|
| Subcellular Fractions | 2 | 2006 | 77 | 0.030 |
Why?
|
| Spider Venoms | 2 | 2006 | 8 | 0.030 |
Why?
|
| Antibodies | 2 | 2007 | 141 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 189 | 0.030 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 2 | 2004 | 7 | 0.030 |
Why?
|
| Alabama | 1 | 2013 | 51 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 51 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2014 | 105 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2006 | 207 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 30 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 195 | 0.030 |
Why?
|
| Anticonvulsants | 2 | 2004 | 34 | 0.030 |
Why?
|
| Adolescent | 1 | 2004 | 5363 | 0.030 |
Why?
|
| Models, Biological | 2 | 2006 | 677 | 0.030 |
Why?
|
| Diuretics | 2 | 2003 | 52 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 260 | 0.030 |
Why?
|
| Peptides | 2 | 2008 | 320 | 0.030 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 808 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2011 | 11 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 515 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 41 | 0.020 |
Why?
|
| Picrotoxin | 1 | 2011 | 14 | 0.020 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2011 | 4 | 0.020 |
Why?
|
| Putrescine | 1 | 2011 | 25 | 0.020 |
Why?
|
| GABA Antagonists | 1 | 2011 | 29 | 0.020 |
Why?
|
| Valine | 1 | 2011 | 31 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 399 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 98 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 141 | 0.020 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2010 | 2 | 0.020 |
Why?
|
| Carcinogens | 1 | 2011 | 124 | 0.020 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2010 | 6 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2004 | 587 | 0.020 |
Why?
|
| Rodentia | 1 | 2010 | 43 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 20 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 41 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2009 | 33 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 293 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1067 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2009 | 25 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 245 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 74 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2009 | 90 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 17 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1455 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2009 | 102 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2008 | 21 | 0.020 |
Why?
|
| Ion Channels | 1 | 2008 | 71 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 142 | 0.020 |
Why?
|
| Thrombin | 1 | 2008 | 25 | 0.020 |
Why?
|
| Reactive Nitrogen Species | 1 | 2008 | 9 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2008 | 79 | 0.020 |
Why?
|
| Integrins | 1 | 2008 | 51 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 160 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2008 | 102 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 52 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 19 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 53 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 80 | 0.020 |
Why?
|
| Shear Strength | 1 | 2007 | 25 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2007 | 15 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2007 | 51 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 33 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 79 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 2006 | 8 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2006 | 17 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 129 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 2006 | 23 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 118 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 37 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 18 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2007 | 233 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 113 | 0.020 |
Why?
|
| Tubercidin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 349 | 0.020 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2006 | 4 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 2006 | 30 | 0.020 |
Why?
|
| DNA Polymerase beta | 1 | 2006 | 13 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 16 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 71 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2007 | 104 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2721 | 0.020 |
Why?
|
| Alleles | 1 | 2006 | 321 | 0.020 |
Why?
|
| Prognosis | 1 | 2008 | 739 | 0.020 |
Why?
|
| Indoles | 1 | 2006 | 158 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2004 | 8 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2004 | 27 | 0.020 |
Why?
|
| Dentate Gyrus | 1 | 2004 | 39 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2005 | 102 | 0.020 |
Why?
|
| Lorazepam | 1 | 2004 | 1 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2004 | 6 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2004 | 57 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2004 | 56 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2004 | 245 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 87 | 0.010 |
Why?
|
| Leukocytes | 1 | 2004 | 72 | 0.010 |
Why?
|
| Microsomes | 1 | 2004 | 52 | 0.010 |
Why?
|
| Denervation | 1 | 2004 | 27 | 0.010 |
Why?
|
| Lysine | 1 | 2004 | 113 | 0.010 |
Why?
|
| Casein Kinases | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 325 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2003 | 16 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 76 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 143 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 40 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2003 | 16 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 16 | 0.010 |
Why?
|
| Lipofuscin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 39 | 0.010 |
Why?
|
| Azo Compounds | 1 | 2003 | 20 | 0.010 |
Why?
|
| Quality Control | 1 | 2003 | 36 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 1354 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 618 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2003 | 38 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2003 | 46 | 0.010 |
Why?
|
| United States | 1 | 2013 | 4223 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2004 | 149 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2002 | 10 | 0.010 |
Why?
|
| Microglia | 1 | 2004 | 166 | 0.010 |
Why?
|
| Electric Capacitance | 1 | 2002 | 7 | 0.010 |
Why?
|
| Limbic System | 1 | 2002 | 25 | 0.010 |
Why?
|
| Caspase 2 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Monocytes | 1 | 2004 | 257 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 661 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 64 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 208 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2002 | 93 | 0.010 |
Why?
|
| Sodium | 1 | 2002 | 103 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2002 | 85 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 938 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 161 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 571 | 0.010 |
Why?
|
| Macrophages | 1 | 2004 | 439 | 0.010 |
Why?
|